Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Surveyor Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Surveyor Capital

Surveyor Capital

Operating

Surveyor Capital: A sector-aligned investment firm, generating alpha through deep understanding of equities.

Location
Chicago, IL, US
Founded
2008
Firm
Compare
Portfolio
Employees

Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding

of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.

Surveyor Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments63
Current Portfolio Count51
Total Portfolio Exits4

Top Investment Stages

Series B30 (52.6%)
Series C11 (19.3%)
Post Ipo Equity7 (12.3%)
Series A6 (10.5%)
Series Unknown3 (5.3%)

Stage Mix

Series B 53%Series C 19%Post Ipo Equity 12%Series A 11%Series Unknown 5%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Remix Therapeutics logo

Remix Therapeutics

Sudo Biosciences logo

Sudo Biosciences

Arvinas logo

Arvinas

Vyne Therapeutics logo

Vyne Therapeutics

Avalyn Pharma logo

Avalyn Pharma

Mariana Oncology logo

Mariana Oncology

Rapport Therapeutics logo

Rapport Therapeutics

Lyra Therapeutics logo

Lyra Therapeutics

ElevateBio logo

ElevateBio

OnKure Therapeutics logo

OnKure Therapeutics

Quanta Therapeutics logo

Quanta Therapeutics

Boundless Bio logo

Boundless Bio

Entact Bio logo

Entact Bio

Karyopharm Therapeutics logo

Karyopharm Therapeutics

Triana Biomedicines logo

Triana Biomedicines

Neuron23 logo

Neuron23

Plexium logo

Plexium

Arkuda Therapeutics logo

Arkuda Therapeutics

Metagenomi logo

Metagenomi

Solve Therapeutics logo

Solve Therapeutics

Immpact Bio logo

Immpact Bio

Ambagon Therapeutics logo

Ambagon Therapeutics

Korro Bio logo

Korro Bio

Arbor Biotechnologies logo

Arbor Biotechnologies

Expansion Therapeutics logo

Expansion Therapeutics

Surveyor Capital - Similar Investment Firms

Desai Capital Management logo

Desai Capital Management

Surrey Capital Partners logo

Surrey Capital Partners

Sandler Capital Management logo

Sandler Capital Management

sandlercap.com

Star Capital logo

Star Capital

Brio Capital Management logo

Brio Capital Management

Sentiment Alpha logo

Sentiment Alpha

Align Capital logo

Align Capital

aligncapital.com

Sequoia Capital Global Equities logo

Sequoia Capital Global Equities

sequoiacap.com

Samara Alpha Management logo

Samara Alpha Management

Engaged Capital logo

Engaged Capital

Observatory Capital logo

Observatory Capital

8 Decimal Capital logo

8 Decimal Capital

Westfield Capital Management logo

Westfield Capital Management

Sentinel Capital Solutions logo

Sentinel Capital Solutions

Tracer Capital logo

Tracer Capital

Surveyor Capital - Classification

Also Known As
  • Surveyor Capital Ltd.
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 2 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
SIC
  • 6000Depository Institutions